Catching you up on the week of April 6–12, 2026: the trial milestones, regulatory moves, and business developments shaping psychedelic medicine right now.
Psyence Biomedical Ltd. (PBM): Psyence expands Australian clinical site network to five sites
Psyence Biomedical said it expanded its Australian clinical trial network from three to five sites, adding Ramsay Health Care and NeuroCentrix. The sites support an ongoing Phase 2b trial run by Southern Star Research testing nature-derived psilocybin (NPX-5) for adjustment disorder in cancer patients in palliative care. The company said the added capacity should accelerate patient enrollment and broaden the study's geographic reach.
Source: globenewswire.com
That's the recap. Follow the Psychedelic Invest Index for how the sector is trading, and check back next week for the next edition.